Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AAPG | 6-K | bullish | 6/10 | Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy Designation (BT | Oct 21, 2026 |
| RZLT | DEF 14A | neutral | 5/10 | Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for seven direct | Oct 21, 2026 |
| STOK | 144 | bearish | 6/10 | Director Edward M. Kaye, MD, filed a Form 144 on October 21, 2026, indicating intent to sell shares of Stoke Therapeutic | Oct 21, 2026 |
| TKNO | 8-K | mixed | 6/10 | Alpha Teknova priced a $40M underwritten public offering of 8M shares at $5.00/share (closing Oct 22), concurrently disc | Oct 21, 2026 |
| TKNO | 424B5 | bearish | 6/10 | Alpha Teknova priced an underwritten public offering of 8,000,000 shares of common stock at $5.00 per share, raising gro | Oct 21, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold a large block of shares on October 19, 2026, exercising options and immediately selling the r | Oct 21, 2026 |
| HELP | 6-K | neutral | 5/10 | Helus Pharma provided a clinical program update via an investor presentation, reiterating that topline data from the APP | Oct 21, 2026 |
| TCRT | 8-K | bullish | 7/10 | Alaunos Therapeutics filed this 8-K to report that, following its October 13, 2026 acquisition of Velaris Therapeutics a | Oct 21, 2026 |
| RCUS | 424B5 | bearish | 5/10 | Arcus Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock, with th | Oct 21, 2026 |
| PYXS | DEF 14A | bearish | 6/10 | Pyxis Oncology is holding a special meeting on November 13, 2026 to seek stockholder approval to double its authorized c | Oct 21, 2026 |
| CSTL | CLUSTER | neutral | 3/10 | Two Castle Biosciences insiders, including the CEO, sold a combined $384K in open-market sales over a one-week window. T | Oct 21, 2026 |
| DWTX | SC 13D/A | neutral | 4/10 | Sealbond Ltd, the majority owner of Dogwood Therapeutics, filed Amendment No. 3 to its Schedule 13D, reporting a new pri | Oct 21, 2026 |
| MEDP | 8-K | bullish | 6/10 | Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY) and GAAP diluted EPS of $4.84, slightly below consensus estimate | Oct 21, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis Pharmaceuticals' partner GSK announced FDA approval of HIBSAGO (bepirovirsen) for chronic hepatitis B, a first-in- | Oct 21, 2026 |
| NEU | INST-CLUSTER | bearish | 4/10 | Three asset managers trimmed their NEU positions by a combined $10.2M in Q3 2026, while one small advisor doubled a $634 | Oct 21, 2026 |
| RCUS | 8-K | neutral | 4/10 | Arcus Biosciences disclosed a preliminary Q3 2026 cash balance of ~$694M, down from $876M at Q2 end and $1.01B at year-e | Oct 21, 2026 |
| CRL | INST-CLUSTER | bullish | 4/10 | Five institutional buyers accumulated $54.4M in CRL during Q3 2026, led by Assenagon Asset Management's $44.6M doubling | Oct 21, 2026 |
| KRYS | INST-CLUSTER | neutral | 3/10 | Four institutional asset managers increased their KRYS positions in Q3 2026, led by Congress Asset Management adding $3. | Oct 21, 2026 |
| IONS | INST-CLUSTER | mixed | 3/10 | A mixed institutional cluster in IONS for Q3 2026 shows two small asset managers adding modest positions (net +$13K) whi | Oct 21, 2026 |
| ABT | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in ABT for Q3 2026 shows four asset managers adding $277.1M in aggregate (led by Assenagon | Oct 21, 2026 |
| IRD | 8-K | neutral | 2/10 | Opus Genetics announced the transition of Chief Scientific and Development Officer Ashwath Jayagopal, effective October | Oct 21, 2026 |
| GNTA | 6-K | bearish | 6/10 | Genenta Science received a Nasdaq minimum bid price deficiency notice on October 16, 2026, as its ADSs closed below $1.0 | Oct 21, 2026 |
| INDP | SC 13D/A | neutral | 4/10 | Ting Yang filed Amendment No. 3 to Schedule 13D, reporting a decrease in beneficial ownership to 6.48% of Indaptus Thera | Oct 21, 2026 |
| VKTX | PRESS-RELEASE | neutral | 1/10 | Viking Therapeutics, Inc announced it will report its Q3 2026 results on October 28, 2026. | Oct 21, 2026 |
| NATR | PRESS-RELEASE | neutral | 1/10 | Nature's Sunshine Products, Inc. announced it will host a conference call on November 4, 2026 to discuss its Q3 2026 res | Oct 21, 2026 |
| NUVB | PRESS-RELEASE | neutral | 1/10 | Nuvation Bio, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| CTKB | PRESS-RELEASE | neutral | 1/10 | Cytek Biosciences, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| RVMD | PRESS-RELEASE | neutral | 1/10 | Revolution Medicines, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| GNTA | PRESS-RELEASE | bearish | 7/10 | Genenta Science received a Nasdaq deficiency notice for failing to maintain a minimum $1.00 bid price for 30 consecutive | Oct 21, 2026 |
| BCRX | PRESS-RELEASE | neutral | 1/10 | BioCryst Pharmaceuticals, Inc. announced it will report its Q3 2026 results on November 4. | Oct 21, 2026 |